Papacostas Michael F, Luckett Peter, Hupp Susan
a Department of Pediatrics, Division of Critical Care , University of Texas Southwestern , Dallas , TX , USA.
Expert Rev Respir Med. 2017 Oct;11(10):815-826. doi: 10.1080/17476348.2017.1358089. Epub 2017 Aug 18.
Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.
气道分泌物潴留发生于疾病过程中，可导致气道堵塞、肺不张及呼吸力学恶化，使得气道廓清成为重要的治疗靶点。涵盖领域：有多种旨在增强气道分泌物清除的药物。我们将综述可用于增强气道廓清的药物、其作用机制以及在急性病患者中使用这些药物的现有证据。专家评论：在囊性纤维化（CF）人群中，使用其中一些药物已显示对肺功能有有益作用。在非CF人群中，关于这些药物的证据有限。虽然一些研究发现了益处，但证据质量较低，难以得出结论。虽然某些患者可能受益，但目前不推荐在无CF的急性病患者中普遍使用这些药物。
